Key result
Paclitaxel-eluting stent shows very late thrombosis 20 months after primary PCI for STEMI.
Why the study?
The incidence and overall risk of late thrombosis of drug-eluting stents after primary PCI for STEMI are not well defined due to limited evidence-based data.
Case Report (n=1)
Highlights the risk of very late stent thrombosis (20 months) with paclitaxel-eluting stents deployed during primary PCI for STEMI.
Late DES thrombosis after primary PCI for STEMI remains incompletely quantified; this cohort extends sparse observational data but leaves risk estimates open.
Drug-eluting stents, despite being very effective in reducing restenosis after percutaneous coronary interventions, are associated with a low but definite risk of late thrombotic occlusion with adverse clinical events. To date, the incidence and overall risk of late thrombosis of drug-eluting stents after primary percutaneous coronary interventions for ST-elevation myocardial infarction are not well defined because of the relative paucity of evidence-based data. We report the case of an angiographically confirmed paclitaxel-eluting stent thrombosis, occurring 20 months after successful primary percutaneous coronary intervention in a 41-year-old woman. To the best of our knowledge, this is the most delayed case of paclitaxel-eluting stent thrombosis described so far.
No takes yet. Share an insight, caveat, or question.
Rigattieri et al. (2006) conducted a case report in ST-elevation myocardial infarction (n=1). Paclitaxel-eluting stent was evaluated on Very late stent thrombosis. Angiographically confirmed paclitaxel-eluting stent thrombosis occurred 20 months after successful primary percutaneous coronary intervention for ST-elevation myocardial infarction in a 41-year-old woman.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: